At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,096 enrolled
Drug / intervention
Nivolumab +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
In Brief
A Phase 3 clinical trial evaluating Nivolumab, Ipilimumab, and 1 other intervention for Advanced Renal Cell Carcinoma and Metastatic Renal Cell Carcinoma. Completed, enrolled 1,096 participants across 189 sites in 28 countries.
Detailed Summary
The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Mexico, Netherlands, Poland, South Korea, Spain, Sweden, Taiwan, Turkey (Türkiye), United Kingdom, United States
CollaboratorsOno Pharmaceutical Co., Ltd.
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 2014
Enrollment StartOct 2014
Primary CompletionJun 2017
Study CompletionMar 2025
TodayJul 2026
First PostedSep 4, 2014
Enrollment StartOct 16, 2014
Primary CompletionJun 26, 2017
Study CompletionMar 21, 2025
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 11.8 years ago
Interventions
Nivolumabbiological
Ipilimumabbiological
Sunitinibdrug